Hikma Pharmaceuticals (HIK) Competitors

Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Do insiders and institutionals hold more shares of HIK or HCM?

42.1% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.5% of HUTCHMED shares are owned by institutional investors. 30.5% of Hikma Pharmaceuticals shares are owned by insiders. Comparatively, 39.0% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the media refer more to HIK or HCM?

In the previous week, Hikma Pharmaceuticals had 6 more articles in the media than HUTCHMED. MarketBeat recorded 7 mentions for Hikma Pharmaceuticals and 1 mentions for HUTCHMED. Hikma Pharmaceuticals' average media sentiment score of 0.63 beat HUTCHMED's score of -0.14 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hikma Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better earnings and valuation, HIK or HCM?

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.74B	1.41	£353.21M	£101.91	18.59
HUTCHMED	£771.01M	3.04	-£52.98M	-£3.92	-55.13

Does the MarketBeat Community favor HIK or HCM?

Hikma Pharmaceuticals received 607 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 78.40% of users gave HUTCHMED an outperform vote while only 70.62% of users gave Hikma Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Hikma Pharmaceuticals	Outperform Votes 803 70.62%	Underperform Votes 334 29.38%
HUTCHMED	Outperform Votes 196 78.40%	Underperform Votes 54 21.60%

Is HIK or HCM more profitable?

Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.71% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	9.45%	12.71%	9.40%
HUTCHMED	-6.87%	-5.71%	-5.90%

Which has more volatility & risk, HIK or HCM?

Hikma Pharmaceuticals has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Do analysts rate HIK or HCM?

Hikma Pharmaceuticals currently has a consensus price target of GBX 2,436.67, suggesting a potential upside of 28.58%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
HUTCHMED	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Hikma Pharmaceuticals beats HUTCHMED on 14 of the 18 factors compared between the two stocks.